This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Pate, G. E. Articles by Foley, J. B. Search for Related Content PubMed PubMed Citation Articles by Pate, G. E. Articles by Foley, J. B. Social Bookmarking                         What's this?

Anti-inflammatory Effects of Statins in Patients with Aortic Stenosis

M. Naeem Tahir, MB

Ross T. Murphy, MD

J. Brendan Foley, MD

Department of Cardiology, CresT Directorate, St. James's Hospital, Dublin 8, Ireland

Background: Aortic stenosis is an inflammatory process, as evidenced by increased tissue expression and serum levels of various endothelial cellular adhesion molecules. Aortic stenosis and atherosclerosis have many risk factors in common, including hypercholesterolemia. In atherosclerosis, statins lower cholesterol and display some anti-inflammatory activity. We hypothesized that statins might also have anti-inflammatory effects in patients with aortic stenosis.

Methods: This observational cross-sectional study measured levels of cellular adhesion molecules in 129 patients (88 male, mean age 68) with aortic stenosis (mean echo gradient 49 mm Hg, range 22 to 112) and compared levels in patients already on statin therapy for primary or secondary prevention of coronary artery disease, to those not on treatment. Concomitant conditions included hypertension (47%), diabetes (10%), and ischemic heart disease (54%). A comparison group consisted of 45 patients with stable ischemic heart disease.

Results: Patients on statins (35) were more likely to have hypertension (62% vs 42%, P = .05), but no significant differences existed in sex, age, concomitant ischemic heart disease, or diabetes. Statin-treated patients had a 20% lower vascular cellular adhesion molecule level than those without (484 ± 143 ng/L vs 604 ± 245 ng/L, P = .006). The reduction in cellular adhesion molecule levels was consistent in patients with aortic stenosis alone, aortic stenosis and ischemic heart disease, or ischemic heart disease alone. There were no differences in the levels of the other adhesion molecules between the three groups, or related to statin therapy.

Conclusion: Statin therapy is associated with reduced serum levels of vascular cellular adhesion molecules in patients with aortic stenosis. Vascular cellular adhesion molecule levels are similar in patients who have aortic stenosis, ischemic heart disease, or both. A prospective study is required to confirm this finding and to determine whether this suppression of endothelial inflammation translates into a slowing of the progression of aortic stenosis.

Key Words: adhesion molecules • cholesterol • aortic stenosis • statins

Journal of Cardiovascular Pharmacology and Therapeutics, Vol. 8, No. 3, 201-206 (2003)
DOI: 10.1177/107424840300800305


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				D. Chua and K. Kalb Statins and Progression of Calcified Aortic Stenosis Ann. Pharmacother., December 1, 2006; 40(12): 2195 - 2199. [Abstract] [Full Text] [PDF]

				V. Liebe, M. Brueckmann, M. Borggrefe, and J. J. Kaden Statin therapy of calcific aortic stenosis: hype or hope? Eur. Heart J., April 1, 2006; 27(7): 773 - 778. [Abstract] [Full Text] [PDF]

				M.-C. Drolet, E. Roussel, Y. Deshaies, J. Couet, and M. Arsenault A High Fat/High Carbohydrate Diet Induces Aortic Valve Disease in C57BL/6J Mice J. Am. Coll. Cardiol., February 21, 2006; 47(4): 850 - 855. [Abstract] [Full Text] [PDF]

				D. W. Quinn Jr. and S. A. Spinler Efficacy of statins in preventing progression of aortic stenosis Am. J. Health Syst. Pharm., May 1, 2005; 62(9): 979 - 981. [Full Text] [PDF]